Drugs / MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine
last change Aug 2010 re-read 2 minutes ago

MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine

Vaccine

Developed for
neuroblastoma · osteosarcoma · rhabdomyosarcoma
Investigated by
Penn State University

Trials 1 · a red edge is where a trial was stopped

2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00944580 Jun 2009 → Aug 2010 neuroblastoma, osteosarcoma, rhabdomyosarcoma Penn State University Withdrawn No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00944580
Modality Vaccine “MAGE-A1, MAGE-A3, and NY-ESO-1 VaccineNCT00944580